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SUMMARY
We recently identified the multipass transmembrane
protein SERINC5 as an antiviral protein that can
potently inhibit HIV-1 infectivity and is counteracted
byHIV-1 Nef.We now report that the anti-HIV-1 activ-
ity, but not the sensitivity to Nef, is conserved among
vertebrate SERINC5 proteins. However, a Nef-resis-
tant SERINC5 became Nef sensitive when its intra-
cellular loop 4 (ICL4) was replaced by that of Nef-sen-
sitive human SERINC5. Conversely, human SERINC5
became resistant to Nef when its ICL4 was replaced
by that of a Nef-resistant SERINC5. In general, ICL4
regions from SERINCs that exhibited resistance to
a given Nef conferred resistance to the same Nef
when transferred to a sensitive SERINC, and vice
versa. Our results establish that human SERINC5
can be modified to restrict HIV-1 infectivity even in
the presence of Nef.
INTRODUCTION
Nef is an accessory protein of HIV-1 and other primate immu-
nodeficiency viruses that is crucial for efficient virus repli-
cation in infected individuals and for virus pathogenicity
(Deacon et al., 1995; Kestler et al., 1991). Although Nef is
not an essential viral gene, it robustly enhances virus
spreading in cultures of quiescent primary CD4+ T lympho-
cytes (Miller et al., 1994; Spina et al., 1994). Nef hijacks
the clathrin-associated protein complex 2 (AP-2) adaptor to
induce the internalization of the viral receptor CD4 (Aiken
et al., 1994; Chaudhuri et al., 2007; Garcia and Miller, 1991).
In addition, Nef downregulates numerous other cell surface
proteins (Haller et al., 2014), including certain major histocom-
patibility class I molecules, which is thought to protect in-
fected cells from cytotoxic T cells (Collins et al., 1998;
Schwartz et al., 1996).
Nef also enhances the specific infectivity of progeny virions
(Aiken and Trono, 1995; Chowers et al., 1994; Miller et al.,
1995). This function of Nef requires its presence during virus
production, but Nef has no detectable effect on the encapsida-
tion of the genomic viral RNA, the incorporation of Env, or the
morphology or stability of the mature core (Aiken and Trono,
1995; Forshey and Aiken, 2003; Schwartz et al., 1995). Neverthe-
less, Nef increases the efficiency of reverse transcription in
target cells (Aiken and Trono, 1995; Chowers et al., 1995;
Schwartz et al., 1995). The effects of Nef on HIV-1 infectivity
are determined by variable HIV-1 Env regions (Usami and Go¨tt-
linger, 2013) and are dependent on clathrin-mediated endocy-
tosis (Pizzato et al., 2007; Usami et al., 2014).
We and others have identified the multipass transmembrane
proteins SERINC3 and SERINC5 as antiviral proteins that are
incorporated into Nef-deficient HIV-1 virions and counter-
acted by Nef (Matheson et al., 2015; Rosa et al., 2015; Usami
et al., 2015). SERINC5 in particular can dramatically inhibit
the infectivity of Nef-deficient HIV-1 (Matheson et al.,
2015; Rosa et al., 2015; Usami et al., 2015). Although
primary HIV-1 Env proteins often confer significant resistance
against SERINC5, virion-associated SERINC5 sensitizes even
resistant Envs to some neutralizing antibodies (Beitari et al.,
2017).
HIV-1 Nef removes SERINC3 and SERINC5 from the cell
surface (Matheson et al., 2015; Rosa et al., 2015; Usami
et al., 2015) and prevents their incorporation into progeny vi-
rions (Rosa et al., 2015; Usami et al., 2015). In contrast, Nef
increased the cell surface expression of SERINC1 (Matheson
et al., 2015), indicating that SERINC3 and SERINC5 are selec-
tively downregulated. Furthermore, the effects of HIV-1 Nef
proteins on SERINC3 and SERINC5 are strain dependent.
For instance, the Nef proteins of the primary HIV-1 isolates
97ZA012 and 93BR020 strongly inhibit the incorporation of
SERINC3 and SERINC5 into virions; in contrast, the Nef
protein of the T cell line-adapted strain SF2 is only active
against SERINC5 (Usami et al., 2015). Thus, Nef proteins
can discriminate among SERINC family members. However,
the determinants that govern sensitivity to Nef remain
unknown.
We show that an intracellular loop of human SERINC5 con-
fers sensitivity to widely divergent Nefs in the context of a
Nef-resistant vertebrate SERINC5 and confers sensitivity to
NefSF2 in the context of human SERINC3, which is normally
resistant to this particular Nef. Human SERINC5 acquired
resistance against Nefs from different HIV-1 clades when this
intracellular loop was replaced by the corresponding region
from a Nef-resistant SERINC5. Altogether, our results identify
a major determinant of Nef responsiveness and establish
that human SERINC5 can be made resistant to Nef-induced
downregulation.
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RESULTS
Anti-HIV-1 Activity, but Not Sensitivity to Nef, Is
Conserved among Vertebrate SERINC5 Orthologs
As little as 100 ng of a relatively weak (pBJ5-based) SERINC5
expression plasmid is sufficient to potently inhibit the single-cycle
infectivity of Nef HIV-1 virions (Usami et al., 2015). Under the
sameconditions,mouseSERINC5 reduced the specific infectivity
of Nef HIV-1 virions produced in 293T cells to a similar extent
(40- to 50-fold) as human SERINC5 (Figure 1A). Zebrafish (Danio
rerio) SERINC5, which is only 61% identical to human SERINC5,
reduced progeny virus infectivity 13- or 21-fold when 100 or
500 ng of expression vector were used, respectively (Figure 1A).
Next, we examined the sensitivities of mouse and zebrafish
SERINC5 to NefSF2, which selectively inhibits the incorporation
of human SERINC5 into HIV-1 virions (Usami et al., 2015).
Although the inhibitory effect of mouse SERINC5 on Nef
HIV-1 produced in 293T cells was clearly counteracted by NefSF2
expressed in trans, the effect of zebrafish SERINC5 was unaf-
fected by NefSF2 (Figure 1B). We infer that widely divergent
SERINC5 proteins share the ability of human SERINC5 to inhibit
HIV-1 infectivity, but not necessarily its sensitivity to Nef.
Transfer of Nef Sensitivity to a Nef-Resistant SERINC5
Because zebrafish SERINC5 was somewhat less active against
Nef HIV-1 than human SERINC5, we also tested the SERINC5
protein of the Western clawed frog (Xenopus tropicalis). Frog
SERINC5 expressed from pBJ5 inhibited the single-cycle infec-
tivity of NefHIV-1 progeny virionswith a potency comparable to
that of human SERINC5 (Figure 2A). However, whereas human
SERINC5 is efficiently counteracted by NefSF2 (Usami et al.,
2015), the inhibitory effect of frog SERINC5 expressed from
pBJ5 on Nef HIV-1 was unaffected by NefSF2 (Figure 2C).
Even when expressed from pBJ6, which lacks an SV40 origin
required for episomal amplification, as well as SV40 enhancer
sequences (Rosa et al., 2015), frog SERINC5 reduced the spe-
cific infectivity of Nef HIV-1 more than 40-fold, and this inhibi-
tory effect largely persisted in the presence of NefSF2 expressed
in trans (Figure 2C). In the absence of exogenous SERINC5, the
effect of NefSF2 on the infectivity of Nef
 HIV-1 virions was quite
modest in these experiments (Figure 2C), perhaps because 293T
cells express only low levels of endogenous SERINC5 (Usami
et al., 2015).
We subsequently used frog SERINC5 as a recipient of
human SERINC5 sequences to identify determinants that
confer sensitivity to NefSF2. The transmembrane hidden Markov
model (TMHMM) membrane protein topology prediction method
(Krogh et al., 2001) predicts that SERINC5 has 10 transmem-
brane helices, and our previous findings indicate that the loop
connecting helices 7 and 8 is surface exposed (Usami et al.,
2015). This in turn suggested that the loop connecting helices
8 and 9 represents the fourth and longest intracellular loop (Fig-
ure 2B). To examine the role of this region, we replaced intracel-
lular loop 4 (ICL4) of frog SERINC5 (fS5) with that of human
SERINC5 (hS5) (Figure 2B). The resulting fS5/hS5-ICL4 chimera
largely retained the ability of frog SERINC5 to inhibit the specific
infectivity of NefHIV-1 progeny virions but lostmuch of its resis-
tance to NefSF2 expressed in trans (Figure 2C). Thus, the transfer
of the ICL4 of human SERINC5 was sufficient to confer substan-
tial sensitivity to NefSF2.
As previously reported (Usami et al., 2015), the incorporation
of hemagglutinin (HA)-tagged human SERINC5 into progeny
virions was strongly inhibited by NefSF2 (Figure 2D, lanes
1 and 2). In contrast, the incorporation of frog SERINC5 was
only slightly affected by NefSF2 (Figure 2D, lanes 3 and 4).
Finally, the effect of NefSF2 on the incorporation of the
fS5/hS5-ICL4 chimera resembled its effect on human
SERINC5 (Figure 2D, lanes 5 and 6). We conclude that the
transfer of the ICL4 was sufficient to allow NefSF2 to signifi-
cantly inhibit both the anti-HIV-1 effect and the virion incorpo-
ration of frog SERINC5.
The ICL4 of Human SERINC5 Confers Sensitivity to
Widely Divergent Nefs
Unlike NefSF2 (clade B), which selectively inhibits the incorpora-
tion of human SERINC5 into HIV-1 virions, Nef97ZA012 (clade C)
also inhibits the incorporation of human SERINC3 (Usami et al.,
2015). Nevertheless, the inhibitory effect of frog SERINC5
onHIV-1 infectivity was essentially unaffected byNef97ZA012 (Fig-
ure S1A), as was the incorporation of frog SERINC5 into HIV-1
virions (Figure S1B). In contrast, Nef97ZA012 enhanced the spe-
cific infectivity of Nef HIV-1 produced in the presence of the
fS5/hS5-ICL4 chimera about 13-fold (Figure S1A) and strongly
inhibited the incorporation of the chimeric protein (Figure S1B).
Thus, the ICL4 of human SERINC5 conferred sensitivity to
HIV-1 Nefs from different subtypes.
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Figure 1. Anti-HIV-1 Activity, but Not
Responsiveness to Nef, Is Conserved
among SERINC5 Orthologs
(A) Human, mouse, and zebrafish SERINC5 pro-
teins share the ability to inhibit the specific
infectivity of HIV-1 progeny virions.
(B) NefSF2 expressed in trans in virus producer
cells counteracts the effect of exogenous mouse,
but not zebrafish, SERINC5 on Nef HIV-1 prog-
eny virion infectivity.
Bar graphs represent the mean + SD from 3 bio-
logical replicates.
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We also observed that the LL164,165AA AP-2 binding site
mutant of NefLAI, which does not counteract SERINC5 (Rosa
et al., 2015), was more abundant in HIV-1 virions produced in
the presence of the fS5/hS5-ICL4 chimera than of frog SERINC5
(Figure S1C). Because frog SERINC5 and the fS5/hS5-ICL4
chimera were incorporated about equally in the absence of a
functional Nef (Figure S1B), this finding provides indirect evi-
dence for a physical interaction between Nef and the ICL4 of
human SERINC5.
Because the ability to counteract SERINC5 is conserved
among all primate lentiviral lineages (Heigele et al., 2016), we
additionally examined the effects of simian immunodeficiency
virus (SIV) Nefs. SIVmac239 Nef increased the specific infectivity
of Nef HIV-1 produced in the presence of frog SERINC5 or of
the fS5/hS5-ICL4 chimera 17- or 27-fold, respectively (Fig-
ure S1D). Thus, SIVmac239 Nef counteracted even unmodified
frog SERINC5. In contrast, unmodified frog SERINC5was largely
resistant to the Nef proteins of SIVagm155 and SIVagm677, and the
transfer of the ICL4 of human SERINC5 substantially increased
its sensitivity to these Nefs (Figures S1E and S1F). Overall,
these findings demonstrate that the ICL4 of human SERINC5
can confer sensitivity to Nefs from widely divergent primate
lentiviruses.
Transfer of Sensitivity against NefSF2 to SERINC3
Unlike other HIV-1 Nefs, NefSF2 has no effect on the incorpora-
tion of SERINC3 into HIV-1 virions (Usami et al., 2015). To
examine whether the ICL4 of SERINC5 confers sensitivity to
NefSF2 in the context of human SERINC3 (hS3), we generated
the hS3/hS5-ICL4 chimera, which harbors the ICL4 of human
SERINC5 in a human SERINC3 background (Figure S2A).
Although the incorporation of authentic human SERINC3 was
unaffected by NefSF2, as previously reported (Usami et al.,
2015), the incorporation of the chimera was strongly inhibited
(Figure S2B), confirming the role of the ICL4 in determining Nef
sensitivity.
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Figure 2. Transfer of Human SERINC5 ICL4 Is Sufficient to Confer Nef Responsiveness to Frog SERINC5
(A) Frog SERINC5 is as potent as human SERINC5 in inhibiting the single-round infectivity of Nef HIV-1 progeny virions.
(B) Schematic illustration of the parental SERINC5 proteins and of the chimera examined.
(C) Effect of frog SERINC5 on Nef HIV-1 progeny virion infectivity is largely resistant to NefSF2 but becomes sensitive upon replacement of its ICL4 by that of
human SERINC5. SERINCs were expressed from pBJ5 or from the very weak pBJ6 expression plasmid.
(D) Western blots showing the effects of NefSF2 on the incorporation of human, frog, and chimeric SERINC5 into Nef
 HIV-1 virions.
Bar graphs represent the mean + SD from 3 biological replicates.
See also Figures S1, S2, and S4.
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Transfer of Nef Resistance to Human SERINC5
The results described earlier showed that the fS5/hS5-ICL4
chimera gained sensitivity to various Nefs. We also made the
reciprocal hS5/fS5-ICL4 chimera (Figure 3A), which inhibited
the infectivity of Nef HIV-1 virions carrying EnvHXB2 as
potently as authentic human SERINC5 (Figures 3B and 3C).
Although the infectivity of Nef HIV-1 virions carrying the rela-
tively SERINC5-resistant EnvJRFL was inhibited to a lesser
extent as expected (Rosa et al., 2015), the hS5/fS5-ICL4
chimera again was at least as potent as human SERINC5 (Fig-
ure 3D), confirming that it retained full anti-HIV activity.
Crucially, whereas NefSF2 increased the infectivity of progeny
virions carrying EnvHXB2 about 37-fold in the presence of exog-
enous human SERINC5, only a 2-fold increase was observed
in the presence of the hS5/fS5-ICL4 chimera (Figure 3B).
Furthermore, similar results were obtained with Nef97ZA012
(Figure 3C). Consistent with these observations, the incorpora-
tion of the hS5/fS5-ICL4 chimera into HIV-1 virions was not
inhibited by NefSF2 and was only moderately reduced by
Nef97ZA012 (Figure 3E). As expected, both Nef proteins strongly
inhibited the incorporation of authentic human SERINC5 (Fig-
ure 3E). We conclude that the hS5/fS5-ICL4 chimera exhibits
marked resistance to HIV-1 Nef proteins.
We also replaced the ICL4 of human SERINC5 with that of hu-
man SERINC2 (hS2), which exhibits no sequence similarity in this
region. The resulting hS5/hS2-ICL4 chimera (Figure 4A) inhibited
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Figure 3. ICL4 of Frog SERINC5 Confers
Resistance to Nef
(A) Schematic illustration of the parental SERINC5
proteins and of the chimera examined.
(B) Human SERINC5 bearing the ICL4 of frog
SERINC5 remains fully capable of inhibiting the
infectivity of Nef HIV-1 virions but exhibits strong
resistance to a clade B HIV-1 Nef.
(C) SERINC5 chimera also exhibits resistance to a
clade C HIV-1 Nef.
(D) SERINC5 chimera inhibits the infectivity of
Nef HIV-1 virions carrying a relatively resistant
HIV-1 Env at least as well as the parental human
SERINC5.
(E) Western blots showing the effects of clade B
and clade C HIV-1 Nefs on the incorporation of
human SERINC5 and of the SERINC5 chimera into
Nef HIV-1 virions.
Bar graphs represent the mean + SD from 3 bio-
logical replicates.
See also Figure S4.
the specific infectivity of Nef HIV-1
virions, albeit less potently than authentic
human SERINC5 (Figure 4B). In this
experiment, NefSF2 increased virion
infectivity more than 50-fold in the pres-
ence of exogenous human SERINC5 but
less than 2-fold in the presence of the
chimera. Furthermore, the incorporation
of the hS5/hS2-ICL4 chimera into HIV-1
virions was essentially resistant to NefSF2
(Figure 4C). In addition, flow cytometry
revealed that the surface expression of SERINC5(iHA), which
contains an internal HA tag within an extracellular loop, was
not compromised when its ICL4 was replaced with that of
SERINC2; it also revealed that the ICL4 swap conferred resis-
tance to downregulation by NefSF2 (Figure S3). Altogether, these
results establish that the ICL4 swapmarkedly reduced the sensi-
tivity of human SERINC5 to NefSF2.
During the course of these experiments, we observed that
the incorporation of human SERINC2 into Nef HIV-1 virions,
although unaffected by NefSF2, is inhibited by Nef97ZA012 (Fig-
ure 4D). Similarly, the incorporation of the hS5/hS2-ICL4
chimera, while unaffected by NefSF2, was clearly inhibited by
Nef97ZA012 (Figure 4E). Because the hS5/fS5-ICL4 chimera,
which differs only in the ICL4, was resistant to Nef97ZA012 (Fig-
ure 3C), these findings raise the possibility that Nef97ZA012 recog-
nizes a determinant within the ICL4 of SERINC2. In addition,
these findings suggest that only ICL4 regions derived from
SERINCs that exhibit resistance to a given Nef confer resistance
to the same Nef when transferred to a sensitive SERINC.
Point Mutations in the ICL4 of Human SERINC5 Confer
Resistance to Nef
Although Nef typically targets dileucine- or tyrosine-based
sorting motifs, such motifs are not evident within the ICL4 of
human or mouse SERINC5 (Figure S4A). To examine which re-
gion of the ICL4 determines sensitivity to Nef, we generated
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versions of Nef-resistant frog SERINC5 that have relatively
poorly conserved segments replaced by the corresponding
human SERINC5 sequences (Figure S4A). We observed that
the transfer of ICL4 residues 9–26, but not of ICL4 residues
26–41, of human SERINC5 significantly increased the sensi-
tivity of frog SERINC5 to NefSF2 (Figure S4B). Within the
9–26 segment, a leucine residue (L350 in human SERINC5) is
present in Nef-sensitive, but not in Nef-resistant, SERINC5
proteins (Figure S4A). Point mutations that targeted this resi-
due (L350A) or another small hydrophobic residue nearby
(I353A) reduced the sensitivity of human SERINC5 to NefSF2
about 8- or 3-fold, respectively (Figure S4C). Together, these
mutations (L350A/I353A) reduced the sensitivity of human
SERINC5 more than 12-fold, and an 8-fold reduction was
observed when L350 and I353 were replaced by the corre-
sponding residues in frog SERINC5 (L350T/I353M) (Fig-
ure S4C). We also observed that the L350A and L350A/I353A
mutations rendered the incorporation of human SERINC5
into HIV-1 virions largely resistant to NefSF2 (Figure S4D).
These findings confirm the crucial role of the ICL4 in Nef
sensitivity.
DISCUSSION
This study shows that widely divergent SERINC5 proteins from
different vertebrate species share the ability to markedly inhibit
the infectivity of Nef HIV-1 virions. However, sensitivity to
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Figure 4. ICL4 of Human SERINC2 Confers
Resistance to NefSF2, but Not Nef97ZA012
(A) Schematic illustration of the parental human
SERINC proteins and of the chimera examined.
(B) Inhibitory activity of human SERINC5 bearing
the ICL4 of human SERINC2 on Nef HIV-1
progeny virion infectivity is largely resistant to
NefSF2. Bar graphs represent the mean + SD from
3 biological replicates.
(C) Western blots showing that the incorporation
of the SERINC chimera into Nef HIV-1 virions is
largely unaffected by NefSF2 expressed in trans.
The incorporation of the chimera was analyzed in
duplicate to document reproducibility.
(D)Western blots showing that the incorporation of
human SERINC2 into Nef HIV-1 virions is unaf-
fected by NefSF2 but inhibited by Nef97ZA012.
(E) Western blots showing that Nef97ZA012 inhibits
the incorporation of human SERINC5 bearing the
ICL4 of human SERINC2 into Nef HIV-1 virions.
See also Figures S3 and S4.
Nef is not conserved and can be trans-
ferred to a Nef-resistant SERINC5 by
exchanging the ICL4 region. In the same
manner, human SERINC3 can be made
sensitive to a particular Nef, supporting
the crucial role of the ICL4 region in Nef
sensitivity. Conversely, our results show
that the anti-HIV-1 activity of human
SERINC5 can be made to persist even
in the presence of Nef, which might pro-
vide a novel strategy to combat HIV-1. However, the in vivo sig-
nificance of the effect of Nef on SERINC5 remains to be
established.
Nearly the entire ICL4 region is predicted to be flexible by the
PROFbval program (Schlessinger et al., 2006). The apparent
flexibility of the ICL4 could conceivably facilitate interactions
with widely divergent Nef proteins through a mechanism
involving conformational selection (Boehr et al., 2009). Our
data show that the ICL4 of human SERINC5 can confer sensi-
tivity to Nefs from different primate lentiviral lineages.
The conservation of the anti-HIV activity among vertebrate
SERINC5 proteins indicates that this activity is closely related
to the biological function of SERINC5, which remains to be eluci-
dated. SERINCs have been named for their reported function as
carrier proteins that facilitate the synthesis of serine-derived
lipids (Inuzuka et al., 2005). This activity suggested a model in
which SERINCs inhibit HIV-1 infectivity by modifying the lipid
content of progeny virions. However, a study argues strongly
against this hypothesis by showing that SERINC5 does not alter
the lipid composition of HIV-1 progeny virions or the exposure of
phosphatidylserine on their surface (Trautz et al., 2017).
Usami et al. (2015) and Rosa et al. (2015) have presented
evidence indicating that Nef counteracts SERINC5 by prevent-
ing its incorporation into HIV-1 virions. More recent work
confirmed that Nef excludes SERINC5 from virions but sug-
gested that Nef additionally inactivates the antiviral activity of
any SERINC5 that becomes virion-associated even in the
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presence of Nef as a consequence of overexpression (Trautz
et al., 2016). In the present study, the ability of Nef proteins
to reduce the incorporation of native or chimeric versions of
frog or human SERINC5 correlated well with their ability to
enhance HIV-1 infectivity, which supports the notion that virion
exclusion is the primary mechanism by which Nef counteracts
SERINC5.
The ability of Nef to counteract human SERINC5 depends on
the AP-2 clathrin adaptor complex (Rosa et al., 2015), whose
cargo-binding AP2M1 and AP2S1 subunits in particular are
more than 95% identical in human, frog, and zebrafish. Nef
also hijacks clathrin adaptors to downregulate CD4 and major
histocompatibility complex class I (MHC class I) molecules,
and in these cases, Nef:AP complexes recognize linear epitopes
within the cytosolic domains of CD4 and MHC class I molecules
(Jia et al., 2012; Ren et al., 2014). Our results indicate that certain
small hydrophobic residues within the ICL4 of human SERINC5
are critical for its sensitivity to Nef, and it is tempting to speculate
that the region containing these residues is also recognized by
Nef:AP complexes.
EXPERIMENTAL PROCEDURES
Analysis of Virus Infectivity
Pseudovirions capable of a single round of replicationwere produced by trans-
fecting 293T cells using a calcium phosphate precipitation method. The cells
were co-transfected with HXB/Env/Nef (1 mg in the experiments shown in
Figures 1A, 1B, and 2A; 2 mg in all other experiments), a pSVIIIenv-based
plasmid expressing EnvHXB2 or, where indicated, EnvJRFL (0.1 mg in the exper-
iments shown in Figures 1A, 1B, 2A, and 3D; 0.4 mg in all other experiments),
and the indicated amounts of pBJ5- or pBJ6-based plasmids expressing
wild-type or chimeric SERINC5 proteins, or with equimolar amounts of empty
vector. In addition, equal amounts of the nef-deficient pNefFS or of a plasmid
expressing an HIV-1 or SIV Nef were co-transfected where indicated (2 mg in
the experiments shown in Figure 1B and in the left panel of Figure 2C;
0.5 mg in all other experiments). Supernatants containing progeny virions
were harvested 1 day post-transfection, clarified by low-speed centrifugation,
filtered through 0.45-mm pore filters, and then used immediately to infect
TZM-bl indicator cells in triplicate in 6-well plates. Aliquots of the virus stocks
were frozen for HIV-1 capsid (p24) antigen quantitation by a standard ELISA.
Three days post-infection, the indicator cells were lysed, and b-galactosidase
activity induced as a consequence of infection was measured using a kit
(E2000; Promega). Values were normalized for the amount of p24 antigen pre-
sent in the supernatants used for infection.
Analysis of SERINC Incorporation
293T cells were co-transfected with 1 mg HXB/Env/Nef, pBJ5-based
expression plasmids for C-terminally HA-tagged SERINCs or SERINC chi-
meras (0.1 mg, unless indicated otherwise), and the nef-deficient control
plasmid pNefFS or a plasmid expressing an HIV-1 Nef (0.5 mg in the experi-
ments shown in Figures 3E, S1B, S2B, and S4D; 2 mg in the experiments
shown in Figures 2D, 4C, and 4E). Virions released into the medium were pel-
leted through 20% sucrose cushions, and virus- and cell-associated proteins
were detected by western blotting as described (Accola et al., 2000). Because
SERINC proteins are highly prone to aggregation (Usami et al., 2015), samples
used for the detection of SERINCs were not boiled before loading. The
antibodies used were 183-H12-5C against HIV-1 CA, and HA.11 (BioLegend)
against the HA epitope.
Statistical Analysis
Statistical analysis was performed using a two-tailed unpaired t test with
Welch’s correction in case of unequal variance. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001, NS, not significant (p > 0.05).
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